Balyasny Asset Management’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-21,433
| Closed | -$1.01M | – | 2212 |
|
|
2024
Q3 | $1.01M | Buy |
+21,433
| New | +$1.01M | ﹤0.01% | 1321 |
|
|
2024
Q2 | – | Sell |
-146,240
| Closed | -$16.4M | – | 2241 |
|
|
2024
Q1 | $16.4M | Sell |
146,240
-241,686
| -62% | -$27.1M | 0.03% | 539 |
|
|
2023
Q4 | $22.5M | Buy |
387,926
+186,290
| +92% | +$10.8M | 0.04% | 414 |
|
|
2023
Q3 | $6.4M | Buy |
201,636
+8,055
| +4% | +$256K | 0.01% | 720 |
|
|
2023
Q2 | $15.9M | Buy |
+193,581
| New | +$15.9M | 0.04% | 490 |
|
|
2023
Q1 | – | Sell |
-264
| Closed | -$38.7K | – | 2478 |
|
|
2022
Q4 | $38.7K | Sell |
264
-2,277
| -90% | -$333K | ﹤0.01% | 1943 |
|
|
2022
Q3 | $430K | Buy |
2,541
+331
| +15% | +$56K | ﹤0.01% | 1617 |
|
|
2022
Q2 | $255K | Buy |
2,210
+1,069
| +94% | +$123K | ﹤0.01% | 1712 |
|
|
2022
Q1 | $114K | Buy |
1,141
+556
| +95% | +$55.6K | ﹤0.01% | 1772 |
|
|
2021
Q4 | $91K | Buy |
+585
| New | +$91K | ﹤0.01% | 1740 |
|
|
2021
Q2 | – | Sell |
-785
| Closed | -$318K | – | 1915 |
|
|
2021
Q1 | $318K | Buy |
+785
| New | +$318K | ﹤0.01% | 1306 |
|
|
2020
Q4 | – | Sell |
-6,078
| Closed | -$2.83M | – | 1367 |
|
|
2020
Q3 | $2.83M | Buy |
+6,078
| New | +$2.83M | 0.02% | 590 |
|
|
2018
Q4 | – | Sell |
-1,444
| Closed | -$361K | – | 1463 |
|
|
2018
Q3 | $361K | Sell |
1,444
-1,860
| -56% | -$465K | ﹤0.01% | 1236 |
|
|
2018
Q2 | $1.48M | Buy |
+3,304
| New | +$1.48M | 0.01% | 862 |
|